Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

Affiliations

¹ Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, United States.
² Genzada Pharmaceuticals, Sterling, KS, United States.
³ Translational Genomics Research Institute (TGEN), Phoenix, AZ, United States.

Published Erratum

Laurence Booth et al. Front Oncol. 2021.

. 2021 Apr 16:11:677725.

doi: 10.3389/fonc.2021.677725. eCollection 2021.

¹ Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, United States.
² Genzada Pharmaceuticals, Sterling, KS, United States.
³ Translational Genomics Research Institute (TGEN), Phoenix, AZ, United States.

Abstract

[This corrects the article DOI: 10.3389/fonc.2020.01331.].

Keywords: CD95; GZ17-6.02; autophagy; death receptor; doxorubicin; sarcoma.

GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling.
Booth L, West C, Hoff DV, Dent P. Booth L, et al. Front Oncol. 2020 Sep 2;10:1331. doi: 10.3389/fonc.2020.01331. eCollection 2020. Front Oncol. 2020. PMID: 32983965 Free PMC article.